TOP NEWS: US FDA Grants Breakthrough Status To AstraZeneca Treatment

Author: Alliance News
Published On: 04/01/2019

LONDON (Alliance News) - AstraZeneca PLC on Monday said its drug selumetinib has been granted a breakthrough therapy designation in the US for neurofibromatosis type 1.

Neurofibromatosis type 1 is an incurable genetic condition affecting between 1 in 3,000 and 1 in 4,000 people. The disease can cause tumours called plexiform neurofibromas to develop on the the protective layer around the nerves.

These tumours may result in pain, disfigurement, difficulty controlling movement, and breathing problems. They can also become cancerous.

The breakthrough therapy designation applies to the treatment of paediatric patients who are at least three years old that have neurofibromatosis type 1 and plexiform neurofibromas.


Read more here.

Want to view archived newsletters? Click Here!


Sign up to receive the latest neurofibromatosis news and information in your inbox!



Have a story you'd like to share with the NF community? Click Here!